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Abstract
Many patients with systemic autoimmune diseases have signs of a continuous production of type I interferon (IFN) and display
an increased expression of IFN-a-regulated genes. The reason for the on-going IFN-a synthesis in these patients seems to be
an activation of plasmacytoid dendritic cells (pDCs) by immune complexes (ICs), consisting of autoantibodies in combination
with DNA or RNA-containing autoantigens. Such interferogenic ICs are internalized via the FcgRIIa expressed on pDCs,
reach the endosome, and stimulate Toll-like receptor (TLR)-7 or -9, which subsequently leads to IFN-a gene transcription.
Variants of genes involved in both the IFN-a synthesis and response have been linked to an increased risk to develop systemic
lupus erythematosus (SLE) and other autoimmune diseases. Among these autoimmunity risk genes are IFN regulatory factor
5( IRF5), which is involved in TLR signaling, and the signal transducer and activator of transcription 4 (STAT4) that interacts
with the type I IFN receptor. Several other gene variants in the IFN signaling pathway also confer an increased risk to develop
an autoimmune disease. The observations that IFN-a therapy can induce autoimmunity and that many autoimmune
conditions have an on-going type I IFN production suggest that the type I IFN system has a pivotal role in the etiopathogenesis
of these diseases. Possible mechanisms behind the dysregulated type IFNsystem in autoimmune diseases and how the IFN-a
produced can contribute to the development of an autoimmune process will be reviewed.
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The type I interferons (IFNs) are a family of related
proteins, which were originally deﬁned by their capac-
ity to interfere with viral replication in cell cultures (1).
This viral interference was the reason that the name
‘interferon’ was coined. Type I IFN is rapidly pro-
duced during viral invasion and, via inhibition of viral
replication, constitutes our major defense system
against viral infections. Type I IFN also have immu-
nomodulatoryfunctionswhichcanbestbedescribedas
a general activation of immune cells. For instance, type
I IFN induces dendritic cell (DC) maturation and
activation, with increased expression of MHC class I
and II molecules, chemokines and chemokine recep-
tors, as well as co-stimulatory molecules (2). The
development of helper T cells along the Th1 pathway
is promoted, and cytotoxic T cells are stimulated by
type I IFNs (3,4). It can also cause B cell activation,
differentiation, antibody production, and Ig isotype
class switching (5,6). Thus, type I IFN is a potent
immuneadjuvant,andthisobservationhas ledtomany
clinical trials where type I IFN is administered to
patients with both infectious and malignant diseases.
In Uppsala, Professor Gunnar V. Alm at the Biomed-
ical Centre set up a production of type I IFN for
clinical use already in 1980. Buffy coats from blood
centers in Sweden were used, and white blood cells
were infected with Sendai virus for the induction of
IFN production. Puriﬁed IFN was used mainly for
patients with malignancies at the University Hospital
in Uppsala, and beneﬁcial effects were reported in
several diseases (7–10). However, early on several
colleagues in Uppsala noted an increased occurrence
of autoantibodies and autoimmune disease during
type I IFN treatment (11–13). These reports were
the ﬁrst indications of a causative role of type I IFN
in human autoimmune diseases. We noted in a
cohort of patients with malignant carcinoid tumors
that as many as 19% of patients receiving long-
term treatment with IFN-a eventually manifested an
autoimmune disease (14), including systemic lupus
erythematosus (SLE). Pre-existing autoantibodies
were not necessary for development of autoimmunity,
although presence of autoantibodies before IFN-a
therapy considerably increased the risk for autoim-
mune disease. The conclusions from these observa-
tions are that type I IFN can both break tolerance and
promote an on-going autoimmune reaction in man.
The IFN-induced diseases also raised the question of
the possible role of type I IFN in spontaneously
occurring autoimmune diseases. This question has
been intensively studied by several research groups
during the last decade. In this review, the role of
type I IFN in the etiopathogenesis of autoimmune
diseases will be discussed with the focus on important
discoveries by our research group. The potential appli-
cation in clinical practice of our present knowledge of
the type I IFN system will also brieﬂyb em e n t i o n e d .
The type I IFN system
There are 3 different types of IFNs (I–III), and among
them the type I IFNs are the largest family that can be
divided into 5 classes (IFN-a,- b,- w,- e,a n d- k), of
which IFN-a can be further divided into 12 subtypes
encoded by 13 highly homologous genes clustered on
chromosome9.ThetypeIIFNsystemisdeﬁnedasthe
type I IFNs themselves and all inducers, cells, and
molecules involved in the pathways leading to the
production and effects of type I IFN. The type I IFN
proteins bind to the same heterodimeric type I IFN
receptor (IFNAR) consisting of two membrane-
spanning polypeptide chains, IFNAR1 and IFNAR2
(15). Most types of cells can produce small amounts of
type I IFN, but the principal type I IFN producer is the
plasmacytoid dendritic cell (pDC), originally desig-
nated the natural IFN-producing cell and described
in 1982–1983 (16–18). Plasmacytoid dendritic cells
are infrequent but produce up to 10
9 IFN-a molecules
per cell within 24 h upon activation. The type I IFN
genes are strictly regulated, and normally almost no
constitutive IFN-a production can be detected in
healthy individuals. Typically, the type I IFN produc-
tionisinducedbyviruses,bacteria,ormicrobialnucleic
acids when sensed by the pattern recognition receptors
(PRRs), such as Toll-like receptors (TLRs), retinoic
acid inducible gene 1 (RIG-I)-like receptors (RLRs),
and nucleotide oligomerization domain (NOD)-like
receptors (NLRs) (reviewed in (19)). Plasmacytoid
dendritic cells express TLR7 and TLR9 in their
endosomal membranes and can therefore become
activated by pathogens that invade pDC through
receptor-mediated endocytosis. The ﬁrst step in the
activation chain involves myeloid differentiation factor
88 (MyD88) that associates with a complex consisting
of tumor necrosis factor receptor-associated factor
6 (TRAF6) and interleukin receptor associated kinase
(IRAK)1and4.Theseeventsleadtophosphorylationof
IFNregulatoryfactor(IRF)-3,5,and7,translocationto
the nucleus, and ﬁnally transcription of the type I IFN
genes.
Ligation of the IFNAR by type I IFNs initiates
several signal transduction pathways leading to
expression of IFN-stimulated genes (ISGs). The clas-
sical IFNAR signaling pathway is the Jak-Stat pathway
involving Janus family kinases, tyrosine kinase (Tyk)
2 and Jak1. The activated kinases recruit and phos-
phorylate the transcription factors Stat1 and Stat2,
which ﬁnally associate with IRF9. The Stat1/Stat2/
228 L. RönnblomIRF9 complex translocates to the nucleus, binds to
IFN-stimulated response elements (ISRE), and acti-
vates the transcription of hundreds of ISGs (20). The
exact function of the majority of the ISG products is
far from clear. However, some of the mechanisms
conferring an antiviral state have been thoroughly
investigated, showing that type I IFN interferes
with several different steps in viral replication. The
type I IFN induces and activates enzymes, such as
myxovirus resistance MxA, 2’5’-oligoadenylate syn-
thetase, and protein kinase (PKR16), which can
inhibit viral transcription and translation and promote
degradation of viral RNA (21).
Type I IFN also affects many key functions in the
innate and acquired immunity as brieﬂy described
above. Several of these type I IFN effects promote the
activation of immune cells and enhance an immune
response. In addition, IFN-a can induce increased
expression of autoantigens, such as Ro52 (22,23), and
promote the release of autoantigens by induction of
apoptosis (24), which in combination with an activa-
tion of the immune system can promote the devel-
opment of an autoimmune reaction, if the IFN
production is not properly controlled.
SLE and other autoimmune rheumatic
diseases
Compared to rheumatoid arthritis, SLE is a relatively
rare disease, with an incidence of around 5 cases per
100,000 persons among Northern Europeans (25).
There is a clear female preponderance (female to male
ratio is 9:1), and most patients develop the disease
between the ages of 15 and 50 years. SLE is regarded
as the prototype autoimmune disease, and the
reason is that a large number of different autoanti-
bodies are produced in these patients and that most,
if not all, cells in the immune system seem to be
involved in the disease process (26). A prominent
feature in SLE is an immune response to nucleic acid
and associated proteins, which results in autoantibody
production, immune complex (IC) formation, and
organ inﬂammation. Before modern treatment was
introduced, major organ involvement and/or infec-
tions were the most important causes of death.
Today, cardiovascular diseases during late stage of
SLE are one of the most challenging problems. For
instance, in our SLE cohort a total of 10% of the
patients are affected by stroke at a median age of
55 years.
Increased serum levels of IFN were described in
SLE patients more than 30 years ago and initially
suggested to be IFN-g (27) but were later charac-
terized as IFN-a (28). Further studies showed
that serum IFN-a levels correlated to disease activity
and to signs of immune activation, but also to
several clinical disease manifestations (29). Early
on, increased levels of IFN-a-induced proteins,
such as 2’-5’oligoadenylate synthetase (30) and
M x A( 3 1 ) ,c o u l da l s ob ed e m o n s t r a t e di nt h em a j o r -
ity of SLE patients, conﬁrming that bioactive type I
IFN is produced in these patients. When genome-
wide gene expression proﬁling became available,
several research groups observed that a majority of
SLE patients display an increased expression of
type I IFN-regulated genes (an IFN signature),
which is connected to a more severe clinical pic-
ture with nephritis or hematological manifestations
(22,23,32,33). Pediatric SLE patients, who usually
have a more severe disease compared to adult SLE
patients, almost invariably display an IFN signature
at early disease stages (22), which suggests that
activation of the type I IFN system may be especially
important in the initiation of the disease process.
Studies of other rheumatic conditions have dem-
onstrated that several diseases show an IFN signa-
ture in both peripheral blood mononuclear cells
(PBMC) and tissues from affected organs. Patients
with primary Sjögren’ss y n d r o m eh a v ea nI F Ns i g -
nature in specimens from salivary glands but also
in PBMC (34,35). Similarly, this signature can be
found in affected tissues and PBMC from patients
with myositis, systemic sclerosis (SSc), and a sub-
group of patients with RA (36). All these observa-
tions suggest a central and general role of the type I
IFN system in the development of autoimmune
rheumatic diseases. Because pDCs are the key
players in the production of IFN-a, it seems logical
to clarify their role in all these diseases.
The plasmacytoid dendritic cell autoimmune
diseases
In our early studies we noticed that the frequency of
circulating pDCs is markedly reduced in SLE patients
(37,38). However, functional studies of SLE pDC
revealed that remaining single cells upon stimulation
have a normal IFN-a-producing capacity. Several
studies suggest that the reason for the decreased
number of circulating pDCs seems to be a migration
of these cells to tissues, because an increased number
of pDCs can be detected in skin (39,40), lymph nodes
(41), and renal tissue (42) from SLE patients. These
pDCs are activated in vivo and synthesize IFN-a,
which indicates that these cells in fact are responsible
for the continuous IFN-a production seen in SLE
patients. We could also demonstrate IFN-a-contain-
ing cells in salivary gland biopsies from patients
with pSS (43) and myositis (44). Consequently, aber-
rant pDC activation may be an important step in the
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immune diseases.
Inducers of type I IFN production in
autoimmune diseases
Normally, type I IFN synthesis is triggered by viruses,
and the production is tightly regulated and limited in
time. An important ﬁnding was therefore the observa-
tion that sera from SLE patients’ IC have the capacity
speciﬁcally to activate pDCs (45,46). Further studies
revealed that such interferogenic ICs contain nucleic
acids and are internalized via the FcgRIIa expressed on
pDCs (47), reach the endosome, and stimulate the
relevant TLR with subsequent activation of transcrip-
tion factors and IFN-a production (48). This mecha-
nism for induction of type I IFN production has been
demonstrated in vitro for both DNA- and RNA-
containing ICs. The nucleic acid-containing autoanti-
gens in the interferogenic ICs can be generated from
apoptotic or necrotic cells (49), which is relevant given
the increased apoptosis and reduced clearance of apo-
ptotic cells in SLE (50,51). Recent studies have shown
that neutrophils undergoing so-called NETosis also
have the capacity to provide interferogenic autoantigens
(52,53), demonstrating that several pathways can lead
to pDC activation in SLE. The complement compo-
nent C1q has the capacity to decrease the IFN-a
production by interferogenic ICs (54,55), and this
effect may at least partially explain the increased inci-
dence of SLE in C1q-deﬁcient individuals (56).
ICs containing both DNA and RNA have the capac-
ity to activate pDCs, but RNA-containing ICs (RNA-
IC) that trigger TLR7 seem to be especially potent
as IFN-a inducers (57,58). Among these are ICs
generated by autoantibodies against snRNP or SSA
in combination with the appropriate autoantigen.
There is in SLE patients a correlation between serum
IFN-a activity and presence of autoantibodies to
RNA-binding proteins (59). Since some of these auto-
antibodies appear several years before the appearance
of clinically overt SLE disease (60) and show cross-
reactivity with viral epitopes (61), the initial trigger for
the production of antibodies with IFN-a-inducing
capacity could well be a viral infection. This scenario
would connect viral infections with the generation of
interferogenic ICs,whichpartly could explainthelong-
sought connection between infectious diseases and
autoimmunity.
It is important to notice that ICs with the
capacity to trigger pDC to IFN-a production can
be generated by autoantibodies from patients
with all diseases displaying an interferon signature
(43,44,62). So, although it remains to be shown
whether interferogenic ICs in fact are responsible
for the on-going type I IFN production in these
diseases in vivo, our data suggest that this may well
be the case.
The regulation of type I IFN response in
autoimmunity
An obvious question is why the type I IFN system is
not down-regulated in patients with autoimmune
disease, because both type I IFN production and
autoantibody formation regularly occur during infec-
tions. An important ﬁnding was the observation that
pDCs are regulated by other immune cells and that
natural killer (NK) cells enhance the IFN-a response
by pDC stimulated with RNA-IC (63). In contrast,
monocytes have a strong inhibitory effect on the NK
cells, which is mediated via prostaglandin E2, TNF-a,
or reactive oxygen species. Interestingly, this inhibi-
tory function by monocytes is diminished in SLE
patients (63), which may contribute to the continuous
activation of the type I IFN system. Recently, we have
shown that NK cells enhance the pDC response to
RNA-IC via MIP-1b and LFA-1, and that the pDC-
NK cross-talk in SLE is promoted by IL-12 and
IL-18 (64). Much less is known about the role of
the adaptive immune system on the pDC function,
but this is an important area for further studies.
However, it is clear that if we understood the regu-
lation of the type I IFN system, we could develop
more powerful therapeutic strategies.
Gene variants in the type I IFN system and risk
for autoimmunity
Among the many identiﬁed risk genes for SLE, a large
number are connected to pathways that are involved
in the IFN-a production or sensitivity (Figure 1).
The transcription factor IRF5, which is constitutively
expressed in pDC (65), was the ﬁrst identiﬁed gene
directly involved in IFN-a gene activation that was
associated to increased risk for SLE (66). Subsequent
studies have shown that polymorphisms in IRF5 are
important for the susceptibility to several other auto-
immune diseases, including rheumatoid arthritis (67)
and pSS (68). Recently, the allele variants with the
highest probability of being causal in SLE were iden-
tiﬁed and shown to affect the IRF5 expression, which
is increased in PBMC from SLE patients (69). We
have shown that alternative splicing of IRF5 is signif-
icantly up-regulated in PBMC from SLE patients
and that a risk haplotype is associated with the
enhanced IRF5 transcript and protein expression
(70). An IRF5 risk haplotype is associated to a high
serum IFN-a activity in patients and especially in
those with autoantibodies to RNA-binding proteins
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The type I interferon in autoimmune diseases 231or double-stranded DNA (71), linking SLE genetic
susceptibility to the presence of interferogenic ICs.
Recently, we found that also a gene variant of IKBKE
(IKK-e), which is a central signal-transducing mole-
cule for the cytosolic RNA/DNA sensors and TLR4,
is associated with SLE (72).
Among gene products involved in the response to
IFN-a, the STAT4 that interacts with the cytoplasmic
part of the IFNAR (73) is strongly associated to SLE
(74). In SLE patients there is an association between
STAT4 genotype and a more severe phenotype, which
includes nephritis and presence of anti-dsDNA auto-
antibodies (75,76). Polymorphisms in the Janus kinase
TYK2, which binds to IFNAR and is required for
signaling through this receptor, are also associated to
SLE (66,77). These data provide further evidence for a
link between the IFN-a response and the disease
process in SLE. Additional susceptibility genes for
SLE can be involved in the activation of the type I
IFN system by other mechanisms, for instance via
generation of autoantigens that contain nucleic acid
or increased production of autoantibodies causing the
formationofincreasedlevelsofinterferogenicICs(78).
The connection between the type I IFN system
and disease manifestation
Several observations suggest that IFN-a may play
an important role in some of the clinical manifestations
in SLE patients. There is an association between
increased serum levels of IFN-a and fever, skin rash,
and leukopenia (29), which perhaps is not surprising
considering that these symptoms are commonly seen
during viral infections. The IFN-regulated chemokines
are connected to organ damage, which indirectly sup-
ports a role for type I IFN in disease outcome (79).
Among the more speciﬁc SLE manifestations, an early
study observed that patients with lupus psychosis
have detectable levels of IFN-a in the cerebrospinal
ﬂuid(CSF)(80),whichisintriguinggiventheobserved
neuropsychiatric adverse effects during IFN-a treat-
ment (81). Recently, autoantibodies with the ability
to form very potent interferogenic ICs together with
RNA-containing autoantigens were demonstrated in
the CSF of SLE patients with neuropsychiatric mani-
festations (82). These ICs also induced other chemo-
kines and pro-inﬂammatory cytokines of possible
relevance for the CNS manifestations frequently seen
inSLE,whichindicatesthattheinterferogenicICsmay
be directly involved in CNS lupus.
Results from an experimental model suggest that
IFN-a can drive the nephritis and end- organ damage
in SLE (83), and it has been shown that pDCs accu-
mulate in active human SLE nephritis (42). Major
organ involvement in SLE patients, such as nephritis,
is also connected to a more pronounced IFN-a sig-
nature (23), and IFN-a-regulated genes are over-
expressed in the glomeruli from SLE nephritis (84).
The role of IFN-a in the premature atherosclerosis
typically seen in SLE patients is unclear, but the type I
IFN system may contribute to the atherosclerotic
process by several mechanisms (85). For instance,
IFN-a may impair endothelial cell differentiation
(86) and affect platelet function (87), but also promote
foam cell formation (88). Furthermore, pDCs are
present in atherosclerotic plaques from carotid lesions
where they can act, via the IFN-a p r o d u c e d ,a si n ﬂam-
matory ampliﬁers and destabilize the plaque (89).
ThereisalsoapossibilitythatgeneswithinthetypeI
IFN signaling pathway can be used as markers for
organ involvement and severity. Thus, there is an
association between STAT4 genotype and risk for
amoreseverediseasephenotypethatincludesnephri-
tis (75,76) and stroke (90). The latter observation is
interesting,becausetheassociationbetweenaSTAT4
risk variant and stroke was of the same magnitude as
the association between stroke and hypertension,
indicating that autoimmune processes may be very
important for many disease manifestations in SLE,
even those that traditionally are not regarded as auto-
immune. Furthermore, a combination of risk alleles
within the type I IFN signaling pathway dramatically
increases the risk for SLE (76), which illustrates how
geneticmappinginthefutureperhapscouldaidinthe
prediction of risk for disease.
The role of the type I IFN system in the
development of autoimmunity
The many ﬁndings concerning the type I IFN
system in SLE patients have been put together into
an etiopathogenic model of SLE, which also includes
other observations in this disease (Figure 2). This
model was ﬁrst described by us in 1999 (45) and has
subsequently been updated (39,91). It is envisioned
that an initial infection by a virus induces type I IFN
production and release of cellular material from dying
cells. The extracellular autoantigens from apoptotic
and necrotic cells as well as NETs from granulocytes
then trigger B cells to autoantibody production
against RNA and DNA-binding proteins in indivi-
duals prone to autoimmune reactions. ICs will be
formed, which act as endogenous type I IFN inducers
that cause a prolonged stimulation of type I IFN
production by pDC. The excessive release of endog-
enous DNA/RNA in combination with impaired
clearance of apoptotic cell material will facilitate the
generation of interferogenic IC. Several drugs and
environmental factors can contribute to the genera-
tion of autoantigens that can form more ICs. The type
232 L. RönnblomI IFN produced activates B cell differentiation, Ig
switch, and generation of antibody-producing plasma
cells as well as long-lived memory cells. Estrogens will
further aid in the activation of autoreactive B cells.
IFN-a will cause increased exposure of autoantigens
such as Ro52 and prime for enhanced IFN-a pro-
duction by pDC. As a consequence, conventional
DCs and macrophages up-regulate their expression
of co-stimulatory molecules and become more effec-
tive in their antigen presentation. In addition, type I
IFNs prolong the survival of activated T and B lym-
phocytes and suppress regulatory T cells. Taken
together a chronic activation of the type I IFN system
will occur and drive an autoimmune process leading
to chronic inﬂammation and tissue damage in a
vicious circle manner.
IFN-a as a therapeutic target
The development of therapies aiming to inhibit type I
IFN production in autoimmune diseases has been
stimulated by the observation that type I IFNAR
knock-out murine lupus models have a reduced dis-
ease activity (92,93). Results from the ﬁrst phase I
clinical trial using a single injection of anti-IFN-a
monoclonal antibodies in SLE patients were recently
reported (94,95). The anti-IFN-a treatment caused a
dose-dependent inhibition of type I IFN inducible
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Figure 2. The role of the type I interferon system in the etiopathogenesis of systemic autoimmune diseases. A viral infection induces IFN-a
production in pDC and the release of autoantigens from dying cells. The produced IFN-a activates both the innate and adaptive immune
system as described in the text. In individuals with a genetic set-up that causes a strong IFN-a production and/or a marked IFN-a response,
tolerance is broken, and antibodies againstnucleic acid-containing autoantigens are produced. Theseantibodies together with the autoantigens
form interferogenic ICs thatstimulate the pDC to IFN-a synthesis and the B cells to increasedautoantibody production, whichcauses a vicious
circle with a continuous IFN-a production and an on-going autoimmune reaction. NK cells promote the IFN-a production and activated
monocytesdown-regulatethe NK cells,but thislatter functionseemstobe deﬁcientin lupus.Figure modiﬁed from(101).(DC= dendriticcell;
IC = immune complex; IFN = interferon; Mo = monocyte; NK = natural killer; pDC = plasmacytoid dendritic cell; TCR = T cell receptor).
The type I interferon in autoimmune diseases 233genes in both peripheral blood and skin biopsies, as
well as a reduction in clinical disease activity. In
addition, GM-CSF, TNF-a, IL-10, and IL-1b
inducible gene signatures, as well as BAFF mRNA
expression, were neutralized in some patients (96),
demonstrating the close interaction between the type I
IFN system and other pro-inﬂammatory pathways.
The observation that a single injection of an anti-
IFN-a antibody could give a sustained neutralization
of the IFN signature is of particular interest and
supports the view that the on-going production of
IFN-a in SLE is at least partly a result of a self-
perpetuating vicious circle (97). So far, no increase in
serious viral infections has been reported among anti-
IFN-a-treated patients, which could be due to the fact
that, besides IFN-a, several other type I IFNs exist
with strong antiviral activity (98). Whether these latter
type I IFNs are sufﬁciently potent to protect anti-
IFN-a-treated SLE patients from serious complica-
tions during for instance a ﬂu pandemic remains to
be established, and this can only be addressed in
larger clinical trials. Other possible therapeutic targets
exist within the type I IFN system, such as the type I
IFN receptor, the BDCA-2 antigen on pDC (38,99),
or oligodeoxyribonucleotide or oligoribonucleotide
TLR antagonists (100). None of these agents have
been tested so far in human SLE patients.
Conclusion
The type I IFN system is activated in patients with
several systemic autoimmune diseases, which seems to
be of major importance in the disease process.
The genetic and immunological background to the
increased production of IFN-a is to some extent
clariﬁed, but several questions still remain to be
answered. Among these are the mechanisms that
lead to different disease phenotypes, despite a similar
IFN signature, and the optimal way to down- regulate
the type I IFN system. Despite this, a number of
studies that target the increased IFN-a levels in several
autoimmune diseases are in an early clinical phase.
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